"The parts of these two product are under IP filing process and we plan to launch them soon after the complete validation and IP filing is completed (commercial versions possibly by the end of next year-end)," says Mr Kumar.

The company is on the way to become a major player in some of the healthcare efforts going on in India for metabolic syndrome (type 2 diabetes, cardiovascular disease, hypertension), malaria and some cancers. The company has developed reliable and competent tools to address these diseases effectively in an affordable manner. BioCOS is also looking at enhancing its efforts, existing technologies and approaches for customized systems biology and next-generation sequencing applications to manage and analyze data in a seamless manner. These have already been well-accepted by the collaborators and now the company is looking at enhancing the tools to penetrate this business.

"We are also working aggressively to have an impressive patent portfolio in the near future. We have in mind to invite venture capitalists to invest sizeable funds in BioBOS and in its promising R&D programs and products to take them to next level in a win-win situation for both," Mr Kumar concludes.